EVM-16
- Generic Name
- EVM-16
EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced or Recurrent Solid Tumors
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Peking University
- Target Recruit Count
- 78
- Registration Number
- NCT06541639
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath